Uses of Zyatin

Zyatin is classified as a cardiovascular drug, the main active ingredient of the drug is Atorvastatin.
Dosage form: film-coated tablets, each containing 10mg of Atorvastatin and other excipients of the manufacturer. Atorvastatin belongs to the group of HMG-CoA reductase inhibitors, effective in lowering cholesterol. Atorvastatin inhibits cholesterol synthesis by inhibiting the enzyme HMG-CoA reductase (the enzyme that makes cholesterol).
Atorvastatin lowers blood levels of total cholesterol as well as LDL cholesterol (the "bad" cholesterol, which plays a major role in the pathogenesis of coronary artery disease).
Decreased levels of LDL cholesterol significantly slow progression of coronary heart disease. In addition, Atorvastatin also reduces blood triglycerides.
Pharmacokinetics:
Absorption: Atorvastatin is rapidly absorbed after oral administration and is not affected by food. Peak serum concentrations are reached 1-2 hours after dosing. Distribution: plasma protein binding is over 98%, Atorvastatin crosses the blood-brain barrier. Metabolism: Atorvastatin is extensively metabolised in the liver to inactive or inactive metabolites. Elimination: Atorvastatin is eliminated primarily in the faeces, with renal excretion less than 2%.

Zyatin is often used in the following cases:
Treatment of elevated total cholesterol, LDL-cholesterol, apolipoprotein B and triglycerides. Simultaneously, Zyatin is used to increase HDL-cholesterol in patients with primary hypercholesterolemia. Treatment of patients with betalipoproteinemia who have not responded adequately to diet. Lowers total cholesterol and LDL-cholesterol in patients with homozygous familial hypercholesterolemia. Absolutely do not use Zyatin medicine in the following cases:
Hypersensitivity to any ingredient of Zyatin medicine. Progressive liver disease or unexplained persistent elevations in transaminases, Pregnant women, Lactating mothers

To achieve a good treatment effect and ensure safety, the patient needs to follow the treatment prescribed by the doctor. Do not arbitrarily increase or decrease the dose, discontinue the drug or change the route of administration unless requested. Also, do not share Zyatin with others or give it to others to use even if they have the same diagnosis.
Dosage:
Treatment of hypercholesterolemia and mixed dyslipidemia: start with 10-20mg/time/day. In patients requiring a substantial reduction in LDL cholesterol (greater than 45%) may be initiated at a dose of 40 mg once daily. The therapeutic dose range of Zyatin is 10 -80mg once a day. After treatment and dose escalation, blood lipids should be re-evaluated within the next 2-4 weeks to adjust the dose appropriately. Treatment of homozygous familial hypercholesterolemia: 10 - 80 mg/day and in combination with other lipid-lowering measures. Combination treatment: Zyatin can be used in combination with resin to increase the effectiveness of treatment. No dose adjustment of Zyatin is required in patients with renal impairment. How to use: Zyatin is made in the form of tablets and taken orally, can be taken at any time of the day, regardless of the meal.
When you miss a dose, take another dose as soon as you remember. If it is close to the time of the next dose, it can be skipped. Do not take more or double the dose to make up the dose.
When the patient shows signs of overdose, it is necessary to quickly bring to the nearest emergency center for treatment. Family members should bring medical records and all medications the patient has taken before to facilitate diagnosis.

In addition to the therapeutic effect, Zyatin medicine may cause some unwanted effects during use such as: constipation, indigestion, flatulence, abdominal pain, nausea, vomiting, headache, dizziness , .. However, these undesirable effects are usually mild and appear only transient.
To ensure safety, patients need to contact their doctor when any unusual signs appear during the use of Zyatin.

Drugs that can interact with Zyatin drugs such as:
Anticoagulants, indandione: taking Zyatin with Zyatin will prolong bleeding time or prothrombin time. The combination of Digoxin and Zyatin causes an increase in the concentration of Digoxin in the blood. Cyclosporine, erythromycin, gemfibrozil, immunosuppressants, niacin: increased risk of myopathy when co-administered with Zyatin.

It is necessary to rule out secondary causes of dyslipidemia and periodically measure blood lipids before starting treatment with Zyatin. During treatment with Zyatin, if the patient has increased creatine kinase, myositis or liver enzyme levels 3 times higher than normal, the dose should be reduced or the drug discontinued. Zyatin should be used with caution in patients with liver dysfunction and heavy alcohol consumption. Patients should have a reasonable diet before treatment with Zyatin and should be maintained throughout the course of treatment.